Maipl Therapeutics Inc. has outlined preclinical progress with MA-4604, its lead investigational therapy for endometriosis. MA-4604 is an oral nonhormonal prostaglandin F2α receptor (FP) antagonist that offers a differentiated mechanism intended to address key pathological drivers of endometriosis without altering hormone levels.